2203. Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations.
作者: Caiwang Yan.;Meng Zhu.;Yanbing Ding.;Ming Yang.;Mengyun Wang.;Gang Li.;Chuanli Ren.;Tongtong Huang.;Wenjun Yang.;Bangshun He.;Meilin Wang.;Fei Yu.;Jinchen Wang.;Ruoxin Zhang.;Tianpei Wang.;Jing Ni.;Jiaping Chen.;Yue Jiang.;Juncheng Dai.;Erbao Zhang.;Hongxia Ma.;Yanong Wang.;Dazhi Xu.;Shukui Wang.;Yun Chen.;Zekuan Xu.;Jianwei Zhou.;Guozhong Ji.;Zhaoming Wang.;Zhengdong Zhang.;Zhibin Hu.;Qingyi Wei.;Hongbing Shen.;Guangfu Jin.
来源: Gut. 2020年69卷4期641-651页
Although a subset of genetic loci have been associated with gastric cancer (GC) risk, the underlying mechanisms are largely unknown. We aimed to identify new susceptibility genes and elucidate their mechanisms in GC development.
2205. How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery).
作者: Ans Pauwels.;Veerle Boecxstaens.;Christopher N Andrews.;Stephen E Attwood.;Richard Berrisford.;Raf Bisschops.;Guy E Boeckxstaens.;Serhat Bor.;Albert J Bredenoord.;Michele Cicala.;Maura Corsetti.;Fernando Fornari.;Chandra Prakash Gyawali.;Jan Hatlebakk.;Scott B Johnson.;Toni Lerut.;Lars Lundell.;Sandro Mattioli.;Hiroto Miwa.;Philippe Nafteux.;Taher Omari.;John Pandolfino.;Roberto Penagini.;Thomas W Rice.;Philip Roelandt.;Nathalie Rommel.;Vincenzo Savarino.;Daniel Sifrim.;Hidekazu Suzuki.;Radu Tutuian.;Tim Vanuytsel.;Marcelo F Vela.;David I Watson.;Frank Zerbib.;Jan Tack.
来源: Gut. 2019年68卷11期1928-1941页
Antireflux surgery can be proposed in patients with GORD, especially when proton pump inhibitor (PPI) use leads to incomplete symptom improvement. However, to date, international consensus guidelines on the clinical criteria and additional technical examinations used in patient selection for antireflux surgery are lacking. We aimed at generating key recommendations in the selection of patients for antireflux surgery.
2206. Adeno-associated virus in the liver: natural history and consequences in tumour development.
作者: Tiziana La Bella.;Sandrine Imbeaud.;Camille Peneau.;Iadh Mami.;Shalini Datta.;Quentin Bayard.;Stefano Caruso.;Theo Z Hirsch.;Julien Calderaro.;Guillaume Morcrette.;Catherine Guettier.;Valerie Paradis.;Giuliana Amaddeo.;Alexis Laurent.;Laurent Possenti.;Laurence Chiche.;Paulette Bioulac-Sage.;Jean-Frederic Blanc.;Eric Letouze.;Jean-Charles Nault.;Jessica Zucman-Rossi.
来源: Gut. 2020年69卷4期737-747页
Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35%-80%). Recurrent clonal AAV2 insertions are associated with the pathogenesis of rare human hepatocellular carcinoma (HCC) developed on normal liver. This study aimed to characterise the natural history of AAV infection in the liver and its consequence in tumour development.
2209. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells.
作者: Oriol de Barrios.;Lidia Sanchez-Moral.;Marlies Cortés.;Chiara Ninfali.;Nuria Profitós-Pelejà.;M C Martínez-Campanario.;Laura Siles.;Rosa Del Campo.;María Jesús Fernández-Aceñero.;Douglas S Darling.;Antoni Castells.;Joan Maurel.;Azucena Salas.;Douglas C Dean.;Antonio Postigo.
来源: Gut. 2019年68卷12期2129-2141页
Chronic inflammation is a risk factor in colorectal cancer (CRC) and reactive oxygen species (ROS) released by the inflamed stroma elicit DNA damage in epithelial cells. We sought to identify new drivers of ulcerative colitis (UC) and inflammatory CRC.
2210. British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring.
作者: Nigel J Trudgill.;Daniel Sifrim.;Rami Sweis.;Mark Fullard.;Kumar Basu.;Mimi McCord.;Michael Booth.;John Hayman.;Guy Boeckxstaens.;Brian T Johnston.;Nicola Ager.;John De Caestecker.
来源: Gut. 2019年68卷10期1731-1750页
These guidelines on oesophageal manometry and gastro-oesophageal reflux monitoring supersede those produced in 2006. Since 2006 there have been significant technological advances, in particular, the development of high resolution manometry (HRM) and oesophageal impedance monitoring. The guidelines were developed by a guideline development group of patients and representatives of all the relevant professional groups using the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool. A systematic literature search was performed and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) tool was used to evaluate the quality of evidence and decide on the strength of the recommendations made. Key strong recommendations are made regarding the benefit of: (i) HRM over standard manometry in the investigation of dysphagia and, in particular, in characterising achalasia, (ii) adjunctive testing with larger volumes of water or solids during HRM, (iii) oesophageal manometry prior to antireflux surgery, (iv) pH/impedance monitoring in patients with reflux symptoms not responding to high dose proton pump inhibitors and (v) pH monitoring in all patients with reflux symptoms responsive to proton pump inhibitors in whom surgery is planned, but combined pH/impedance monitoring in those not responsive to proton pump inhibitors in whom surgery is planned. This work has been endorsed by the Clinical Services and Standards Committee of the British Society of Gastroenterology (BSG) under the auspices of the oesophageal section of the BSG.
2211. Epidemiology of chronic liver diseases in the USA in the past three decades.
作者: Zobair M Younossi.;Maria Stepanova.;Youssef Younossi.;Pegah Golabi.;Alita Mishra.;Nila Rafiq.;Linda Henry.
来源: Gut. 2020年69卷3期564-568页
Given significant advances in treatment of viral hepatitis and the growing epidemic of obesity, the burden of the different types of liver diseases in the USA may be changing. Our aim was to assess the shift in the prevalence of different liver disease aetiologies in the USA over the past three decades.
2215. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma.
作者: Jiabin Cai.;Lei Chen.;Zhou Zhang.;Xinyu Zhang.;Xingyu Lu.;Weiwei Liu.;Guoming Shi.;Yang Ge.;Pingting Gao.;Yuan Yang.;Aiwu Ke.;Linlin Xiao.;Ruizhao Dong.;Yanjing Zhu.;Xuan Yang.;Jiefei Wang.;Tongyu Zhu.;Deping Yang.;Xiaowu Huang.;Chengjun Sui.;Shuangjian Qiu.;Feng Shen.;Huichuan Sun.;Weiping Zhou.;Jian Zhou.;Ji Nie.;Chang Zeng.;Emily Kunce Stroup.;Xu Zhang.;Brian C-H Chiu.;Wan Yee Lau.;Chuan He.;Hongyang Wang.;Wei Zhang.;Jia Fan.
来源: Gut. 2019年68卷12期2195-2205页
The lack of highly sensitive and specific diagnostic biomarkers is a major contributor to the poor outcomes of patients with hepatocellular carcinoma (HCC). We sought to develop a non-invasive diagnostic approach using circulating cell-free DNA (cfDNA) for the early detection of HCC.
2219. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.
作者: Annieke C G van Baar.;Frits Holleman.;Laurent Crenier.;Rehan Haidry.;Cormac Magee.;David Hopkins.;Leonardo Rodriguez Grunert.;Manoel Galvao Neto.;Paulina Vignolo.;Bu'Hussain Hayee.;Ann Mertens.;Raf Bisschops.;Jan Tijssen.;Max Nieuwdorp.;Caterina Guidone.;Guido Costamagna.;Jacques Devière.;Jacques J G H M Bergman.
来源: Gut. 2020年69卷2期295-303页
The duodenum has become a metabolic treatment target through bariatric surgery learnings and the specific observation that bypassing, excluding or altering duodenal nutrient exposure elicits favourable metabolic changes. Duodenal mucosal resurfacing (DMR) is a novel endoscopic procedure that has been shown to improve glycaemic control in people with type 2 diabetes mellitus (T2D) irrespective of body mass index (BMI) changes. DMR involves catheter-based circumferential mucosal lifting followed by hydrothermal ablation of duodenal mucosa. This multicentre study evaluates safety and feasibility of DMR and its effect on glycaemia at 24 weeks and 12 months.
|